To further confirm these results, we used two colorectal carcinoma cell lines (CHD-1 and HDC-9) with yet unknown mutation status that have been established by our work group in the 1990s [18], [19] and found that the cell line overexpressing Abi1 (CHD-1) carries an activating mutation in codon 13 of KRAS. This evidence concerns the gene KRAS and colorectal carcinoma.